Entera Bio
ENTX
17 hedge funds and large institutions have $10.1M invested in Entera Bio in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
13% more funds holding
Funds holding: 15 → 17 (+2)
4% more capital invested
Capital invested by funds: $9.75M → $10.1M (+$367K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.12% less ownership
Funds ownership: 14.78% → 14.65% (-0.12%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SEIA
Signature Estate & Investment Advisors
Los Angeles,
California
|
+$84K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$36.5K |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$17K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$9.64K |
| 5 |
Renaissance Technologies
New York
|
+$6.39K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$44.1K |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$41.1K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$14.5K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$461 |
ENTX Hedge Fund Activity: Q3 2024 in Review
17 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Entera Bio (ENTX) for Q3 2024, worth a combined $10.1M — up 3.8% from $9.75M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ENTX positions and 1 closed out — a net gain of 2 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Signature Estate & Investment Advisors, opening a new position worth an estimated $84K. The largest seller was UBS Group, cutting an estimated $44.1K.
- 17 institutional investors held Entera Bio (ENTX) as of Q3 2024, up from 15 in Q2 2024.
- Funds reported $10.1M of Entera Bio stock for Q3 2024, up 3.8% quarter-over-quarter.
- 3 funds opened new Entera Bio positions in Q3 2024 and 1 closed out, a net change of +2 holders.
- The largest Entera Bio buyer in Q3 2024 was Signature Estate & Investment Advisors, an estimated $84K added.
- The largest Entera Bio seller in Q3 2024 was UBS Group, an estimated $44.1K sold.
Based on aggregated 13F filings for Q3 2024.